Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

752
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
752

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Dostarlimab and niraparib in primary advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Post-colonoscopy appendicitis: a thought-provoking unresolved entity.

Acta gastro-enterologica Belgica·2024
Same author

Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.

Gynecologic oncology·2024
Same author

Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.

ESMO open·2023

Related Experiment Video

Updated: Mar 5, 2026

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

34.7K

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

A Karam1, J A Ledermann2, J-W Kim3

  • 1COGi, Stanford, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|March 23, 2017
PubMed
Summary

Consensus statements for ovarian cancer treatment trials recommend stratifying patients by surgery type and residual disease. Standard chemotherapy and alternative regimens are detailed, with overall survival as the preferred trial endpoint.

Keywords:
clinical trialsfirst-line chemotherapyovarian cancer

More Related Videos

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
11:29

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Published on: January 22, 2022

15.8K
Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens
05:58

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

Published on: February 4, 2014

14.2K

Related Experiment Videos

Last Updated: Mar 5, 2026

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

34.7K
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
11:29

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Published on: January 22, 2022

15.8K
Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens
05:58

Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens

Published on: February 4, 2014

14.2K

Area of Science:

  • Gynecologic Oncology
  • Clinical Trial Design
  • Evidence-Based Medicine

Background:

  • The Fifth Ovarian Cancer Consensus Conference convened in November 2015 to establish consensus statements on first-line therapies for ovarian cancer.
  • Key areas reviewed included surgical stratification, chemotherapy control arms, and appropriate clinical trial endpoints.

Framework:

  • Surgery: Recommend stratifying patients in first-line trials into primary debulking surgery and neoadjuvant chemotherapy subgroups. Further stratify based on residual disease (absent gross residual disease vs. others).
  • Chemotherapy Control Arms: Intravenous 3-weekly carboplatin and paclitaxel is the standard for advanced ovarian cancer. Acceptable alternatives for trials include weekly paclitaxel with 3-weekly carboplatin, bevacizumab addition, and intraperitoneal therapy.
  • Trial Endpoints: Overall survival is the preferred primary endpoint. Progression-free survival (PFS) is an alternative, but requires overall survival as a secondary endpoint and supported by patient-reported outcomes and subsequent therapy data.

Implementation:

  • These consensus statements provide a framework for designing robust clinical trials in ovarian cancer.
  • Standardized approaches to patient stratification and chemotherapy regimens enhance comparability across studies.
  • Clear endpoint definitions improve the reliability and interpretability of trial results.

Implications:

  • Implementation of these recommendations will lead to more consistent and informative clinical trials for ovarian cancer.
  • Standardized trial designs facilitate meta-analyses and the synthesis of evidence for improved treatment guidelines.
  • Refined trial endpoints ensure that patient-centered outcomes are adequately captured and evaluated.